Chair/CEO at Eli Lilly and Company
Greater Indianapolis
138K followers
500+ connections
About
A Lilly veteran for more than 25 years, with experience in marketing, sales, drug development and international operations. I became CEO in January 2017 and was elected chair of the company’s board of directors effective June 2017.
I serve on the board of Adobe and am the immediate past chair of the board of the Pharmaceutical Research and Manufacturers of America. I’m also a member of the International Federation of Pharmaceutical Manufacturers & Association’s CEO Steering Committee, The Business Council, Business Roundtable, and the U.S. Patent and Trademark Office’s Council for Inclusive Innovation.
I am also a digital media spokesperson for Lilly and discuss topics related to our company, our business, and the health care environment. We operate in a highly regulated environment, and only designated employees can discuss our products or pipeline. If you need information about our products or have questions or concerns, please visit these resources: https://e.lilly/guidelines
Articles by Dave
Activity
-
Indiana took a meaningful step for Hoosiers living with obesity — opting into the CMMI BALANCE demonstration to expand Medicaid coverage of select…
Indiana took a meaningful step for Hoosiers living with obesity — opting into the CMMI BALANCE demonstration to expand Medicaid coverage of select…
Liked by Dave Ricks
-
📣 We're proud to congratulate the 30 Boilermakers represented in IBJ Media’s annual Indiana 250 list for their significant contributions to our…
📣 We're proud to congratulate the 30 Boilermakers represented in IBJ Media’s annual Indiana 250 list for their significant contributions to our…
Liked by Dave Ricks
-
I just wrapped up two incredible days visiting our team in Mexico. Lilly México has been part of Lilly for more than 80 years, and this affiliate is…
I just wrapped up two incredible days visiting our team in Mexico. Lilly México has been part of Lilly for more than 80 years, and this affiliate is…
Liked by Dave Ricks
Experience
Education
Skills
More activity by Dave
-
Expanding access to medicines and building a sustainable business go hand in hand. July 1, millions of eligible Medicare Part D patients may be…
Expanding access to medicines and building a sustainable business go hand in hand. July 1, millions of eligible Medicare Part D patients may be…
Liked by Dave Ricks
-
For 150 years, Lilly has believed that a medicine's job isn't done at approval — it's done when the patient has it. Starting July 1, that belief…
For 150 years, Lilly has believed that a medicine's job isn't done at approval — it's done when the patient has it. Starting July 1, that belief…
Liked by Dave Ricks
-
Obesity has gone untreated for too long, and that needs to change. Starting July 1, a new pathway through the Medicare GLP‑1 Bridge program may allow…
Obesity has gone untreated for too long, and that needs to change. Starting July 1, a new pathway through the Medicare GLP‑1 Bridge program may allow…
Shared by Dave Ricks
-
Data presented so far at #ADA2026 is generating lots of conversation on the conference floor. The science is moving fast and the excitement about the…
Data presented so far at #ADA2026 is generating lots of conversation on the conference floor. The science is moving fast and the excitement about the…
Liked by Dave Ricks
-
New science, new perspectives and a renewed sense of what’s possible for people living with obesity and type 2 diabetes: #ADA2026 moved us forward…
New science, new perspectives and a renewed sense of what’s possible for people living with obesity and type 2 diabetes: #ADA2026 moved us forward…
Liked by Dave Ricks
-
Most people take wakefulness for granted. For people with narcolepsy, that is not an option. Neither is it for the far larger population living with…
Most people take wakefulness for granted. For people with narcolepsy, that is not an option. Neither is it for the far larger population living with…
Liked by Dave Ricks
-
This year, Lilly turns 150 and America turns 250 — built on opportunity, innovation and the freedom to pursue both. When people are healthy, they…
This year, Lilly turns 150 and America turns 250 — built on opportunity, innovation and the freedom to pursue both. When people are healthy, they…
Shared by Dave Ricks
-
Across three Phase 3 studies for investigational use in type 2 diabetes, the data tell a clear story: the highest dose of our once-daily oral GLP-1…
Across three Phase 3 studies for investigational use in type 2 diabetes, the data tell a clear story: the highest dose of our once-daily oral GLP-1…
Shared by Dave Ricks
-
Positive results for patients with biomarker-driven early-stage non-small cell lung cancer to be shared at the ASCO Annual meeting. See more…
Positive results for patients with biomarker-driven early-stage non-small cell lung cancer to be shared at the ASCO Annual meeting. See more…
Liked by Dave Ricks
-
Treating obesity shouldn't be one-size-fits-all. Our patient-centered, scientifically-grounded approach to obesity management includes medicines…
Treating obesity shouldn't be one-size-fits-all. Our patient-centered, scientifically-grounded approach to obesity management includes medicines…
Liked by Dave Ricks
-
Obesity affects more than body weight – it can also impact your heart, your liver, your joints — virtually every organ system in your body That's…
Obesity affects more than body weight – it can also impact your heart, your liver, your joints — virtually every organ system in your body That's…
Liked by Dave Ricks
-
Cardiovascular disease remains the leading cause of death worldwide. Data presented at #EASCongress2026 and published in NEJM Group offer early…
Cardiovascular disease remains the leading cause of death worldwide. Data presented at #EASCongress2026 and published in NEJM Group offer early…
Liked by Dave Ricks
Other similar profiles
Explore more posts
-
David Alderman
❓ 𝐀𝐫𝐞 𝐲𝐨𝐮 𝐫𝐞𝐩𝐥𝐚𝐜𝐞𝐚𝐛𝐥𝐞? ✅ 𝐘𝐞𝐬. 𝐁𝐲 𝐡𝐮𝐦𝐚𝐧𝐬. 🤖 𝐁𝐲 𝐀𝐈. 🦾 𝐁𝐲 𝐡𝐮𝐦𝐚𝐧𝐨𝐢𝐝 𝐫𝐨𝐛𝐨𝐭𝐬. ⚠️ 𝐀𝐈 𝐅𝐚𝐢𝐥𝐬 🇺🇸 𝐁𝐨𝐬𝐭𝐨𝐧: AI scraped filings on an “oncology breakthrough.” It was a shelved patent. Capital misallocated. 🇩🇪 𝐅𝐫𝐚𝐧𝐤𝐟𝐮𝐫𝐭: AI flagged a cardiometabolic “signal” in local chatter. It was rumor dressed as signal. Millions lost. 🇯🇵 𝐓𝐨𝐤𝐲𝐨: AI parsed payer documents in nephrology. It missed fine print. Access collapsed. 🏆 𝐇𝐔𝐌𝐈𝐍𝐓 𝐕𝐢𝐜𝐭𝐨𝐫𝐢𝐞𝐬 🇺🇸 𝐍𝐞𝐰 𝐘𝐨𝐫𝐤: Two senior oncology voices killed a false trial readout before repricing hit. 🇫🇷 𝐏𝐚𝐫𝐢𝐬: HUMINT confirmed prescriber sentiment on GLP-1 switch rates. Forecast secured. 🇦🇺 𝐒𝐲𝐝𝐧𝐞𝐲: HUMINT exposed competitor supply gaps in radioligand therapy. Entry accelerated. 🔀 𝐇𝐲𝐛𝐫𝐢𝐝 𝐖𝐢𝐧-𝐖𝐢𝐧 🇧🇪 𝐁𝐫𝐮𝐬𝐬𝐞𝐥𝐬: AI mapped 2,000 immunology abstracts. HUMINT filtered the noise in three days. The picture was decisive. 📝 𝐒𝐜𝐫𝐚𝐩𝐞 𝐜𝐚𝐧 𝐟𝐚𝐢𝐥. 𝐉𝐮𝐝𝐠𝐦𝐞𝐧𝐭 𝐬𝐞𝐜𝐮𝐫𝐞𝐬. 🎯 𝐓𝐡𝐞 𝐥𝐚𝐬𝐭 𝐦𝐢𝐥𝐞 𝐢𝐬 𝐇𝐔𝐌𝐈𝐍𝐓. #MolekuleIntel #HUMINT #Biopharma #CompetitiveIntelligence #Ecopharmcopolitik
1 Comment -
Sarah Snyder
Breadth MSLs vs. Depth MSLs. Two MSLs at a congress: MSL #1 is juggling 5 products & knows a little about everything. MSL #2 is covering 1 product & knows everything about it. Some people love the variety. Others love the mastery. Neither is “better.” But they feel different. Would you rather cover multiple products as an MSL or focus on one?
31 Comments
Explore top content on LinkedIn
Find curated posts and insights for relevant topics all in one place.
View top content